GlaxoSmithKline plc Stock LIQUIDNET SYSTEMS
Stocks
GSK
GB0009252882
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| Jul. 30 | Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US | RE |
| Jul. 30 | GSK global supply chain director sells 38,000 shares | AN |
| Market Cap | 77.4B 104B 90.41B 84.29B 146B 9,952B 148B 993B 388B 4,961B 391B 384B 16,432B | P/E 2026 * |
12.7x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 95.16B 128B 111B 104B 180B 12,236B 182B 1,220B 478B 6,099B 481B 472B 20,204B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.58x |
| Free-Float |
92.75% | Yield 2026 * |
3.6% | Yield 2027 * | 3.79% |
Last Transcript: GlaxoSmithKline plc
| Jul. 30 | GSK : Deutsche Bank gives a Neutral rating | ZD |
| Jul. 30 | Berenberg raises Rio Tinto; HSBC ups Centrica | AN |
| Jul. 30 | Goldman Sachs still cautious about GSK |  |
| Jul. 29 | GSK : DZ Bank remains Neutral | ZD |
| Jul. 29 | GSK : JP Morgan reaffirms its Sell rating | ZD |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.40% | - | - | 104B | |
| -0.53% | -3.95% | +50.70% | +153.56% | 1,024B | |
| +0.21% | -2.68% | +53.20% | +51.79% | 618B | |
| -2.51% | -3.25% | +28.54% | +68.94% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.69% | -0.30% | +13.76% | +12.83% | 264B | |
| -7.37% | -4.40% | -0.74% | -44.28% | 209B | |
| -0.64% | +2.43% | +29.74% | +65.93% | 208B | |
| -0.82% | +0.70% | +15.05% | +72.05% | 162B | |
| +0.40% | +1.92% | +6.47% | -29.77% | 143B | |
| Average | -1.19% | -1.21% | +26.03% | +42.41% | 379.88B | |
| Weighted average by Cap. | -0.97% | -2.02% | +36.14% | +71.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.99B 45.88B 39.71B 37.02B 64.27B 4,370B 65.09B 436B 171B 2,178B 172B 168B 7,216B | 35.62B 48.08B 41.61B 38.79B 67.35B 4,580B 68.21B 457B 179B 2,283B 180B 177B 7,562B |
| Net income | 6.17B 8.33B 7.21B 6.72B 11.67B 793B 11.82B 79.14B 30.97B 396B 31.21B 30.59B 1,310B | 6.96B 9.39B 8.13B 7.58B 13.16B 895B 13.32B 89.24B 34.92B 446B 35.19B 34.49B 1,477B |
| Net Debt | 17.76B 23.98B 20.75B 19.35B 33.59B 2,284B 34.02B 228B 89.14B 1,139B 89.85B 88.07B 3,772B | 14.52B 19.6B 16.96B 15.81B 27.46B 1,867B 27.81B 186B 72.86B 931B 73.44B 71.98B 3,083B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
